tirzepatide cv outcomes trial and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management 60-Second Journal Club: The SUMMIT

Some of these medications can cause certain withdrawal symptoms or increased health risks if stopped abruptly, so it can be necessary to gradually taper off the medication to prevent these risks

Tirzepatide doesnt require a specific diet, but optimal results come from strategic choices

Nausea typically peaks during the first few weeks after starting Zepbound or increasing the dose, then gradually improves as your body adjusts to the medication

Were looking for individuals who: Are 5570 years old Have a BMI 30, or 27 with a weight-related condition (like high blood pressure, diabetes, or high cholesterol) Have been on a stable dose of medications (if any) for at least 12 weeks Are not using insulin or planning to start an intensive weight-loss or exercise program Are not pregnant or planning pregnancy (see details below) If this sounds like you, you could help us explore a whole new approach to healthy aging

SURPASS-PEDS (NCT05260021) was a 30-week double-blind, placebo-controlled trial with a 22-week open-label extension that randomized 99 pediatric patients 10 years of age and older with type 2 diabetes mellitus with inadequate glycemic control on metformin (69%), or basal insulin (8%), or both (23%) to receive subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, or placebo once weekly as add-on therapy

In severe cases, this could lead to unexpected tooth cracks, chipping, fractures, and tooth loss